Virpax Pharmaceuticals Ownership 2024 | Who Owns Virpax Pharmaceuticals Now?
Institutional Ownership
0.00%
Insider Ownership
6.16%
Retail Ownership
93.84%
Institutional Holders
1.00
Virpax Pharmaceuticals Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
PARALLEL ADVISORS, LLC | 0.00% | - | 1 | - | - | 1 | Jun 30, 2024 |
Virpax Pharmaceuticals's largest institutional shareholder is PARALLEL ADVISORS, LLC, holding 0.00% of the company's total share outstanding, currently valued at $1.00. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
PARALLEL ADVISORS, LLC | 0.00% | - | 1 | - | - | 1 | Jun 30, 2024 |
The largest Virpax Pharmaceuticals shareholder by % of total assets is PARALLEL ADVISORS, LLC. The company owns 1.00 shares of Virpax Pharmaceuticals (VRPX), representing 0.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
PARALLEL ADVISORS, LLC | 0.00% | - | 1 | - | - | 1 | Jun 30, 2024 |
As of Jun 30 2024, Virpax Pharmaceuticals's largest institutional buyer is PARALLEL ADVISORS, LLC. The company purchased 0.00 stocks of VRPX, valued at $1.00.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
PARALLEL ADVISORS, LLC | 0.00% | - | 1 | - | - | 1 | Jun 30, 2024 |
As of Jun 30 2024, Virpax Pharmaceuticals's biggest institutional seller is PARALLEL ADVISORS, LLC. The company sold 0.00 shares of VRPX, valued at $1.00.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|
Virpax Pharmaceuticals Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
VANGUARD VALLEY FORGE FUNDS | 0.01% | 6,400 | - | - | Mar 31, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 132,588 | - | - | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 60,596 | - | - | Feb 29, 2024 |
USAA MUTUAL FUNDS TRUST | 0.00% | 1,126 | - | - | Jan 31, 2024 |
JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 556 | - | - | Mar 31, 2024 |
Virpax Pharmaceuticals's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 6.40K shares, compromising 0.01% of its total assets.
Virpax Pharmaceuticals Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
30 Jun, 24 | 1 | - |
31 Mar, 24 | 1 | -94.12% |
31 Dec, 23 | 17 | 41.67% |
30 Sep, 23 | 12 | -7.69% |
30 Jun, 23 | 13 | -18.75% |
31 Mar, 23 | 16 | -11.11% |
31 Dec, 22 | 18 | 28.57% |
30 Sep, 22 | 14 | 7.69% |
30 Jun, 22 | 13 | - |
31 Mar, 22 | 13 | -18.75% |
31 Dec, 21 | 16 | 45.45% |
30 Sep, 21 | 11 | 83.33% |
30 Jun, 21 | 6 | 50.00% |
31 Mar, 21 | 4 | - |
As of 30 Jun 24, 1 institutions are holding Virpax Pharmaceuticals's shares, representing an increase of 0.00% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
30 Jun, 24 | 1 | - |
31 Mar, 24 | 1 | -100.00% |
31 Dec, 23 | 377,134 | -38.84% |
30 Sep, 23 | 616,674 | -19.42% |
30 Jun, 23 | 765,295 | -31.24% |
31 Mar, 23 | 1,113,021 | -28.32% |
31 Dec, 22 | 1,552,757 | -14.90% |
30 Sep, 22 | 1,824,669 | -2.20% |
30 Jun, 22 | 1,865,661 | -24.95% |
31 Mar, 22 | 2,485,815 | 11.20% |
31 Dec, 21 | 2,235,462 | -6.24% |
30 Sep, 21 | 2,384,134 | 870.60% |
30 Jun, 21 | 245,635 | -10.67% |
31 Mar, 21 | 274,980 | - |
Virpax Pharmaceuticals (VRPX) has 1.00 shares outstanding as of 30 Jun 24, up 0.00% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
30 Jun, 24 | 0.00% | 1000000.00% |
31 Mar, 24 | 0.00% | - |
31 Dec, 23 | 3.22% | 11.62% |
30 Sep, 23 | 5.26% | 12.33% |
30 Jun, 23 | 6.53% | 7.24% |
31 Mar, 23 | 9.50% | 5.41% |
31 Dec, 22 | 13.26% | 5.46% |
30 Sep, 22 | 15.58% | 6.14% |
30 Jun, 22 | 15.93% | 3.53% |
31 Mar, 22 | 21.23% | 1.89% |
31 Dec, 21 | 33.48% | 2.13% |
30 Sep, 21 | 39.66% | 161.64% |
30 Jun, 21 | 4.95% | 10.20% |
31 Mar, 21 | 6.97% | - |
As of 30 Jun 24, Virpax Pharmaceuticals is held by 0.00% institutional shareholders, representing a 1000000.00% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
30 Jun, 24 | - | - |
31 Mar, 24 | - | -100.00% |
31 Dec, 23 | 11 | 266.67% |
30 Sep, 23 | 3 | 50.00% |
30 Jun, 23 | 2 | -33.33% |
31 Mar, 23 | 3 | -62.50% |
31 Dec, 22 | 8 | 100.00% |
30 Sep, 22 | 4 | -50.00% |
30 Jun, 22 | 8 | - |
31 Mar, 22 | 8 | -38.46% |
31 Dec, 21 | 13 | 30.00% |
30 Sep, 21 | 10 | 233.33% |
30 Jun, 21 | 3 | -25.00% |
31 Mar, 21 | 4 | - |
- institutional shareholders have increased their position in VRPX stock as of 30 Jun 24 compared to - in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
30 Jun, 24 | - | -100.00% |
31 Mar, 24 | 1 | - |
31 Dec, 23 | 1 | -66.67% |
30 Sep, 23 | 3 | - |
30 Jun, 23 | 3 | -40.00% |
31 Mar, 23 | 5 | -16.67% |
31 Dec, 22 | 6 | 50.00% |
30 Sep, 22 | 4 | 100.00% |
30 Jun, 22 | 2 | 100.00% |
31 Mar, 22 | 1 | -50.00% |
31 Dec, 21 | 2 | 100.00% |
30 Sep, 21 | 1 | -50.00% |
30 Jun, 21 | 2 | - |
31 Mar, 21 | - | - |
- institutional shareholders have reduced their position in VRPX stock as of 30 Jun 24 compared to 1 in the previous quarter (a -100.00% decrease).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun, 24 | 1 | - | 1 | - | 0.00% | 1000000.00% | - | - | - | -100.00% |
31 Mar, 24 | 1 | -94.12% | 1 | -100.00% | 0.00% | - | - | -100.00% | 1 | - |
31 Dec, 23 | 17 | 41.67% | 377,134 | -38.84% | 3.22% | 11.62% | 11 | 266.67% | 1 | -66.67% |
30 Sep, 23 | 12 | -7.69% | 616,674 | -19.42% | 5.26% | 12.33% | 3 | 50.00% | 3 | - |
30 Jun, 23 | 13 | -18.75% | 765,295 | -31.24% | 6.53% | 7.24% | 2 | -33.33% | 3 | -40.00% |
31 Mar, 23 | 16 | -11.11% | 1,113,021 | -28.32% | 9.50% | 5.41% | 3 | -62.50% | 5 | -16.67% |
31 Dec, 22 | 18 | 28.57% | 1,552,757 | -14.90% | 13.26% | 5.46% | 8 | 100.00% | 6 | 50.00% |
30 Sep, 22 | 14 | 7.69% | 1,824,669 | -2.20% | 15.58% | 6.14% | 4 | -50.00% | 4 | 100.00% |
30 Jun, 22 | 13 | - | 1,865,661 | -24.95% | 15.93% | 3.53% | 8 | - | 2 | 100.00% |
31 Mar, 22 | 13 | -18.75% | 2,485,815 | 11.20% | 21.23% | 1.89% | 8 | -38.46% | 1 | -50.00% |
31 Dec, 21 | 16 | 45.45% | 2,235,462 | -6.24% | 33.48% | 2.13% | 13 | 30.00% | 2 | 100.00% |
30 Sep, 21 | 11 | 83.33% | 2,384,134 | 870.60% | 39.66% | 161.64% | 10 | 233.33% | 1 | -50.00% |
30 Jun, 21 | 6 | 50.00% | 245,635 | -10.67% | 4.95% | 10.20% | 3 | -25.00% | 2 | - |
31 Mar, 21 | 4 | - | 274,980 | - | 6.97% | - | 4 | - | - | - |
Virpax Pharmaceuticals Insider Shareholders Trades
Open Market Insider Trades
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Open Market Insider Buys
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Insider Sells
All Insider Owners Trades
The last insider sell of Virpax Pharmaceuticals's stock was made by Mathias Sheila on Oct 03 2023, selling 25,000 shares at $4.62 per share (valued at $115.50K).
Virpax Pharmaceuticals Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q1 2024 | 9 | 1 | 900.00% |
Q2 2023 | 3 | - | - |
Q1 2023 | 10 | 1 | 1000.00% |
Q2 2022 | 4 | 1 | 400.00% |
Q1 2022 | 12 | - | - |
Q4 2021 | 2 | - | - |
Q3 2021 | 1 | 1 | 100.00% |
Q2 2021 | 8 | 6 | 133.33% |
Q1 2021 | 2 | 10 | 20.00% |
9 total buy trades, and 1 total sell trades (buy/sell ratio of 9.00%) were made by Virpax Pharmaceuticals's insiders, as of Q1 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q1 2024 | - | - | - |
Q2 2023 | - | - | - |
Q1 2023 | - | - | - |
Q2 2022 | 3 | - | - |
Q1 2022 | - | - | - |
Q4 2021 | 2 | - | - |
Q3 2021 | - | - | - |
Q2 2021 | - | - | - |
Q1 2021 | 2 | - | - |
As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Virpax Pharmaceuticals's stocks.
Virpax Pharmaceuticals Peer Ownership
Ticker | Company |
---|---|
BDRX | Biodexa Pharmaceuticals Plc |
NTRB | Nutriband Inc. |
BWV | Onconetix, Inc. |
KPRX | Kiora Pharmaceuticals, Inc. |
KTTA | Pasithea Therapeutics Corp. |
LGVN | Longeveron Inc. |
REVB | Revelation Biosciences, Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
HILS | Tharimmune, Inc. |
VRAX | Virax Biolabs Group Limited |
RNXT | RenovoRx, Inc. |
PRAX | Praxis Precision Medicines, Inc. |
ABIO | ARCA biopharma, Inc. |
PALI | Palisade Bio, Inc. |
VRPX Ownership FAQ
Who Owns Virpax Pharmaceuticals?
Virpax Pharmaceuticals is owned by institutional shareholders (0.00%), insiders (6.16%), and public (93.84%). The largest institutional shareholder of Virpax Pharmaceuticals is PARALLEL ADVISORS, LLC (0.00% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.01% of total shares).
Who are the major institutional shareholders of Virpax Pharmaceuticals?
Virpax Pharmaceuticals's major institutional shareholders are PARALLEL ADVISORS, LLC. The top five shareholders own together 0.00% of the company's share outstanding.
How many Virpax Pharmaceuticals shareholders are there?
As of Jun 2024, there are 1 institutional shareholders of Virpax Pharmaceuticals.
What percentage of Virpax Pharmaceuticals is owned by PARALLEL ADVISORS, LLC?
PARALLEL ADVISORS, LLC owns 1 shares of Virpax Pharmaceuticals, representing 0.00% of the company's total shares outstanding, valued at $1 (as of Jun 2024).